Anti-asthmatic miR-224-5p inhibits the FHL1/MAPK pathway to repress airway smooth muscle cell proliferation in a murine model of asthma-like airway inflammation

Zhifang Zhuang1,2, Yanjuan Zhou1,2, Jiao Xu1,2 and Leying Pan1,2*

Abstract

Background: The proliferation of airway smooth muscle cells (ASMCs) contributes to the contractility and inflammation in the pathophysiology of asthma. This intrigued us to clarify the effect of microRNA (miR)-224-5p on biological characteristics of ASMCs in mice with asthma-like airway inflammation and responses through the FHL1-dependent MAPK pathway.

Methods: An ovalbumin (OVA)-induced asthma mouse model was established, where ASMCs were isolated. The expression of FHL1 was determined in asthmatic mice. Artificial modulation of FHL1 expression was performed to explore its effect on airway inflammation of asthmatic mice and ASMC proliferation and apoptosis. Afterwards, we analyzed the interaction among miR-224-5p, FHL1 and the MAPK pathway, and explored their combined impacts on airway inflammation of asthmatic mice and ASMC proliferation and apoptosis.

Results: FHL1 was highly expressed and miR-224-5p was poorly expressed in asthmatic mice. FHL1 was verified to be a target of miR-224-5p. Loss of FHL1 function reduced airway inflammation in asthmatic mice and proliferation of ASMCs while inducing their apoptosis. Besides, miR-224-5p inhibited the MAPK pathway by binding to FHL1. Overexpression of miR-224-5p relieved airway inflammation, inhibited ASMC proliferation, and increased apoptosis, which could be reversed by overexpression of FHL1.

Conclusion: Altogether, miR-224-5p inhibited airway inflammation in asthmatic mice and ASMC proliferation through blocking the MAPK pathway by down-regulating FHL1.

Keywords: MicroRNA-224-5p, Four-and-a-half LIM protein 1, MAPK pathway, Airway inflammation, Asthma, Airway smooth muscle cells
ASMCs, and to validate if repression of this migratory potential would offer a therapeutic possibility for asthma management [8, 9].

It is interesting to note that four-and-a-half LIM domain 1 (FHL1), is a member of the FHL subfamily [10], characterized by an N-terminal half LIM domain, the downregulation of which inhibits proliferation of pulmonary artery SMCs [11, 12]. In addition, an isoform of FHL1, KyoT2, can be considered as a potential target for the treatment of asthma since its overexpression downregulates airway remodeling [13] and resistance in asthmatic mice [14]. Interestingly, FHL1 has been involved in various cell pathways including estrogen- [15], Notch-16, and MAPK [17] cascades. It has also been highlighted previously that FHL1 senses the biomechanical stress-induced responses via the MAPK pathway [18]. Interestingly, MAPK pathway activation is associated with those inflammatory responses of patients with asthma [19]. Accumulating evidences have confirmed that p38MAPK pathway activation is responsible for the IFN-γ release in lymphocytes in asthma, contributing to asthmatic inflammation [20, 21]. Hence, we speculated that FHL1 could mediate the MAPK pathway to affect the airway inflammation in asthma.

MicroRNAs (miRNAs) belong to the class of small non-coding RNA molecules and have been identified as important regulators of target genes of some pathways [22]. miRNAs controlling some target genes are important for inflammatory responses and development of asthma [19]. Strikingly, miR-224 is reported to be expressed at a low level in asthmatic patients [23]. Moreover, overexpression of miR-224 is capable of suppressing airway epithelial cell inflammation and airway remodeling in PM2.5-induced asthmatic mice by decreasing the expression of TLR2 [24].

In our study, FHL1 was predicted to be a target of miR-224-5p based on the results from several databases (microRNA, TargetScan, RNA22, and starBase). Given the aforementioned findings, we performed the current study aiming to ascertain the effect of miR-224-5p on the airway inflammation in asthma, which involved FHL1 and the MAPK pathway (Additional file 1: Fig. S1).

**Materials and methods**

**Ethics statement**

This study was approved by the Institutional Animal Care and Use Committee of the Wujin Hospital Affiliated with Jiangsu University, and carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.

**Microarray profiling**

Two asthma-related gene expression datasets (GSE27066 and GSE6858) were retrieved from the GEO database, followed by differential expression analysis. Both of the datasets contained gene expression data from lung tissues of ovalbumin (OVA)-induced asthmatic mice and control mice. The annotated platforms of GSE27066 and GSE6858 datasets were GPL1261-[Mouse430_2] Affymetrix Mouse Genome 430 2.0 Array. Differentially expressed genes (DEGs) were screened using limma package of R language [15], with threshold values set as $p < 0.05$ and $|\text{Log FoldChange (FC)}| > 2$. Then a heatmap of DEGs was plotted. Venn online analysis tool was employed to calculate and plot customized Venn diagrams for comparison of DEGs in the two datasets and determination of asthma-related DEGs. Afterwards, microRNA, TargetScan, RNA22 and starBase databases were applied to predict the miRNAs that regulated FHL1, followed by construction of miRNA-mRNA regulatory network.

**Murine asthma-like airway inflammation model establishment and animal grouping**

A total of 90 male or female BALB/c mice (weighing 13–18 g and aged 7 weeks) were provided by Animal Core Facility of Jiangsu University (Jiangsu, China). Among them, 80 mice were selected for asthma-like airway inflammation modeling and the other 10 was set as normal control. Each mouse was intraperitoneally injected with 200 μL sensitization solution (20 μg OVA and 150 μL aluminum hydroxide adjuvant) at days 0 and 14 [16]. Additionally, these mice were treated with 1% OVA by daily intranasal inhalations from day 21 to day 55 (20 min each time). During the operation, the activity and respiration of mice were observed. Besides, the remaining 10 mice were treated with autoclaved phosphate-buffered saline (PBS; pH = 7.4) instead as normal control.

Mice in the normal group had mild symptoms such as scratching, sneezing or cough, but mice after sensitization operations exhibited asthma-like symptoms such as irritability, scratching, sneezing or coughing, and shortness of breath. As inhalations increased, these symptoms were aggravated. Meanwhile, these mice were found arched or lying motionless with symptoms including cyanosis in nose and mouth, ears and toes, decreased appetite, polycopria, thin sloppy stool, as well as lackluster hair, indicating the successful model establishment.

After anesthesia, successfully modeled asthmatic mice were grouped (n = 10) including an asthma group wherein mice remained untreated and other treatment groups subjecting to administration with lentivirus carrying...
overexpression (oe)-FHL1, short hairpin RNA (sh)-FHL1, miR-224-5p-agomir, miR-224-5p-agomir + oe-NC, or miR-224-5p-agomir + oe-FHL1, or the negative control (NC) (oe-NC, sh-NC or NC-agomir). The corresponding lentivirus was intranasally administered into mice at a titer of $5 \times 10^7$ TU/mL (200 µL per mouse) from day 26 once a week until day 47 [25]. The lentiviral vectors were purchased from Shanghai GenePharma (Shanghai, China).

The mice were euthanized on day 55 after the successful establishment of asthma-like airway inflammation. The bronchoalveolar lavage fluid (BALF) in the right lung was obtained by intratracheal infusion. Then the BALF was centrifuged (3000 r/min) for 10 min whereupon the supernatant was collected and stored at −70 °C for further use. The left lung of mice was made into paraffin-embedded slices for hematoxylin–eosin (HE) staining. The flow chart of in vivo experiments is shown in Additional file 2: Fig. S2.

Assessment of airway responsiveness
Mice were anesthetized with pentobarbital sodium on day 55. The mice were then subjected to trachea cannula with connection to a breathing machine and atomization device along with Buxco spirometer, by which the airway responsiveness of mice was measured on the 1st, 3rd and 7th day. Subsequently, the trachea was exposed and cannulated to a small-animal ventilator controlled by computer. Next, the mice were ventilated with a tidal volume of 10 mg/kg at a frequency of 150 breaths/min and a positive end-expiratory pressure of 2 cm H2O to reach a mean lung volume, which is close to that during spontaneous breathing. Each mouse was exposed to PBS and then to increasing concentrations of methacholine (Mch) in PBS (0, 10, 30, 100, and 200 mg/mL). The peak airway responses to the inhaled Mch were recorded. With Mch as the activator, the inspiratory resistance (RI) caused by two-fold dosage of Mch (0.39–200 g/L) was examined until the original RI value was doubled. The dosage of Mch was switched into logarithm (PC100) for statistical analysis. Higher PC100 value represented lower airway reactivity [26, 27].

Immunohistochemistry
Paraffin-embedded tissue blocks of left lung were sectioned into 4-µm tissue slices, which were treated with 3% alcohol and hydrogen peroxide (H2O2). After antigen retrieval and goat serum blocking, the slices were incubated with rabbit monoclonal antibody to FHL1 (1: 500; ab255828; Abcam, Cambridge, UK), rabbit monoclonal antibody to vascular endothelial growth factor (VEGF; 1: 250; ab32152; Abcam), rabbit monoclonal antibody to p-ERK1/2 (1: 100; ab214362; Abcam), rabbit monoclonal antibody to p-p38MAPK (1: 500, ab47363; Abcam) and rabbit monoclonal antibody to p-JNK (1: 100; ab124956; Abcam) overnight at 4 °C, and then re-probed with the secondary antibody, horseradish peroxidase (HRP)-labeled goat anti-rabbit immunoglobulin G (IgG) H&L (1: 1000; ab6721; Abcam) at 37 °C for 20 min. Subsequently, the slices were supplemented with OVA solution (Hebei Bio-high Technology, Shijiazhuang, Hebei, China) at 37 °C for 20 min. The slices were then counterstained by hematoxylin for 1 min, hydrolyzed by 1% hydrochloric acid ethanol, and observed under the light microscope. Five high-power visual fields were randomly selected for each slice selects with 100 cells per field. The cells stained to be brown were regarded as positive cells, and the percentage of positive cells was counted.

HE staining
Prepared sections of mouse lung tissues were stained with hematoxylin (Solarbio, Beijing, China) for 2 min. Afterwards, the slices were rinsed by distilled water for 1 min and stained by eosin for 1 min. At last, pathological changes of the slices were observed under a microscope (XP-330, Bingyu Optical Instrument, Shanghai, China).

Masson’s trichrome staining
The lung tissue sections were stained successively with Regaud’s hematoxylin dye solution for 5—10 min and Masson’s dye solution for 5—10 min. After being immersed in 2% acetic acid solution, sections were hydrolyzed by 1% molybdate solution. Following that, the slices were stained with aniline blue and aqua anion dye liquor, and observed under a microscope. At last, collagen deposition in lung tissues was observed under the microscope. Collagen fibers were stained to be blue, the cytoplasm of muscle fibers stained to be purplish red, and the nucleus stained to be blue brown [28]. NIH ImageJ image analysis software was used to quantitatively analyze the collagen deposition area. The percentage of collagen deposition area = collagen fiber/tissue area × 100%.

BALF cell counting
The BALF pellets were resuspended with 0.5 mL precooled and sterile PBS. Then total cell number was measured with 0.1 mL BALF by a blood cell count plate and 0.2 mL diluted suspension was dropped in the clean slide. Wright’s-Giemsa staining solution A was dropped to the slide. The slide was stained with Wright’s-Giemsa staining solution B for 10 min. On the basis of cell morphology and color, 300 white blood cells were tested for cell counting. Also, the numbers of total cells
and eosinophils in BALF were observed under an optical microscope.

**ELISA**

The BALF supernatant of mice was collected to determine the levels of interleukin (IL)-4 (18.75 pg/mL—1200 pg/mL, ab221833), IL-5 (2.05 pg/mL—500 pg/mL, ab100711), IL-13 (1.95 pg/mL—125 pg/mL, ab219634) and IFN-γ (2.74 pg/mL—2000 pg/mL, ab100689) using ELISA kits (Abcam).

**Isolation and identification of primary ASMCs**

The mice were euthanized with intraperitoneal anesthesia (0.1 mL/20 g) of the mixture of ketamine and droperidol at a ratio of 1: 1. After being sterilized with 75% alcohol, the chest was cut open to isolate the trachea and lung tissues, which were put into the D-Hanks’s solution containing 100 U/mL mycillin at 4 °C.

The tissue blocks (≤1 mm) were transferred into a 15 mL centrifuge tube, and detached with 2 mL prepared collagenase type I solution containing 2 mg/mL collagenase type I, 2.5 mg/mL papain and 2.5 mg/mL bovine serum albumin solution, and D-Hanks’s solution in a 5% CO₂ incubator for 25 min at 37 °C. DMEM medium supplemented with high glucose and FBS was applied to stop the detachment. Then the tissue blocks were centrifuged at 178 × g for 5 min. After the supernatant was discarded, the tissue blocks were detached with 2 mL 0.25% trypsin and 0.02% EDTA solution again for 15 min, followed by centrifugation. At last, the tissue blocks were added with 1.5 mL 20% DMEM with high glucose containing FBS for semi-open incubation and then further cultured with replaced solution after 3 d. Immunohistochemical streptavidin–biotin-peroxidase (SP) staining for ASMC-specific α-actin presented positive to identify ASMCs. The morphology of ASMCs incubated at the 3rd day and 8th day was observed under an inverted microscope.

**Cell transduction**

The ASMCs at passage 3 were trypsinized and seeded in a 24-well plate. Cells were assigned into normal (ASMCs isolated from normal mice), asthma (ASMCs isolated from asthmatic mice), NC-mimic, miR-224-5p mimic, NC-inhibitor, miR-224-5p inhibitor, sh-NC, sh-FHL1, oe-NC, oe-FHL1, miR-224-5p mimic + oe-NC, and miR-224-5p mimic + oe-FHL1 groups. Upon reaching 30–50% cell confluence, cells were transduced with corresponding plasmids using Lipofectamin 2000 reagents (11,668–019, Invitrogen, CA) and then incubated for 6–8 h. The medium was renewed with complete medium for another incubation for 24–28 h. Plasmids were constructed by Sangon Biotech (Shanghai, China).

**Dual-luciferase reporter assay**

On the basis of bioinformatically predicted miR-224-5p binding site in FHL1 mRNA 3’-untranslated region (3’-UTR), the wild type (WT) and mutant (mut) sequences were designed and synthesized with the use of Xho I and Not I double restriction-enzyme digestion. The synthesized fragments were cloned into the PUC57 vector, which was then identified using DNA sequencing assay, and sub-cloned to the psiCHECK-2 vector. Next, plasmids were transferred into Escherichia coli DH5α to amplify the plasmid. The plasmids were extracted using Omega plasmid miniprep kit (D1100-50 T, Solarbio).

Based on protocols of a dual luciferase assay kit (D0010, Solarbio), the luciferase intensity was determined by a Glomax20/20 luminometer (E5311, Zhongmei Biotechnology, Xi’an, Shaanxi, China).

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)**

TRizol reagents (15,596–018, Solarbio) were applied to extract total RNA from lung tissues and transfected ASMCs. Primers of miR-224-5p, FHL1, ERK, p38MAPK and JNK were designed and synthesized by Takara (Dalian, China) (Additional file 4: Table S1). The extracted RNA was reverse transcribed into complementary DNA (cDNA) utilizing the PrimeScript RT kit (RR036A, Takara, Tokyo, Japan). The fluorescence quantitative PCR operation was subsequently carried out as per the instructions of the SYBR® Premix Ex TaqTM II kit (RR820A, TaKaRa, Tokyo, Japan) on an ABI 7500 instrument (Applied Biosystems, Foster City, CA). As normalized to U6 or GAPDH, relative expression was determined by the quantitative method 2−△△Ct.

**Western blot analysis**

Total protein was extracted from mouse left lung tissues or ASMCs using a RIPA kit (R0010, Solarbio), with the concentration measured by a bicinchoninic acid (BCA) kit (G3522-1, GBCBIO Technologies, Guangzhou, Guangdong, China). The proteins were then wet-transferred onto polyvinylidene fluoride (PVDF) membranes after polyacrylamide gel electrophoresis separation. After 1-h blocking with 5% BSA, the membranes were then incubated with the following diluted primary antibodies: rabbit monoclonal antibody to FHL1 (1: 1000; ab255828; Abcam), rabbit monoclonal antibody to p-ERK1/2 (1 μg/ml; 1: 100; ab184699; Abcam), mouse monoclonal antibody to p38MAPK (1: 1000; ab31828 Abcam), rabbit monoclonal antibody to JNK (1: 1000; ab179461; Abcam), rabbit monoclonal antibody to p-JNK (1: 100; ab184699; Abcam), rabbit monoclonal antibody to p-p38MAPK (1: 500, ab47363; Abcam), rabbit monoclonal antibody to p-ERK1/2 (1: 100; ab184699; Abcam).
were expressed as mean ± standard deviation. The measurement data comparisons posttest. Data among multiple groups at various time points were analyzed by two-way ANOVA with Bonferroni corrections. \( p < 0.05 \) was considered statistically significant.

### Results

**FHL1 is highly expressed in mice with asthma-like airway inflammation**

Through profiling of asthma-related gene expression datasets GSE27066 and GSE6858, the top 200 DEGs of the two datasets were identified, respectively. Through the intersection, there was only one gene (FHL1) in the Venn diagram (Fig. 1A), highlighting FHL1 as an asthma-associated gene. A heatmap was then plotted based on the expression of top 30 asthma-related DEGs obtained from the GSE6858 dataset (Fig. 1B), which displayed higher FHL1 expression in the asthma samples than that in the control samples. FHL1 was also found to be abnormally overexpressed in asthma samples in the GSE27066 dataset (Fig. 1C).

In established asthmatic mice, an increase in airway responsiveness was observed when Mch exceeded 30 mg/mL (Fig. 1D). The bronchial lumen of similar diameters in the lung tissue sections was subjected to HE staining. The results (Fig. 1E) illustrated that the asthmatic mice presented with thicker airway epithelium and airway smooth muscle (ASM), and inflammatory cell infiltration under the mucous membrane. In addition, compared with the normal mice, the percentages of total inflammatory cells and eosinophils were increased in the BALF of asthmatic mice (Fig. 1F).

Next, the secretion of inflammatory factors, as reflected by levels of IL-4, IL-5, IL-13 and IFN-\( \gamma \) in the BALF supernatant determined by ELISA, was increased in asthmatic mice relative to normal mice (Fig. 1G). Immunohistochemistry analysis demonstrated that the positive rates of FHL1 and VEGF proteins were increased in lung tissues of asthmatic mice (Fig. 1H).

The aforementioned results suggested that the mouse asthma models were successfully established, where FHL1 exhibited a high expression.

**MiR-224-5p targets and downregulates FHL1 in ASMCs**

MicroRNA and other databases were utilized to predict the upstream miRNAs that regulate FHL1, which were intersected to obtain the 11 miRNAs (Fig. 2A). Of note, among the 11 candidates miR-224-5p has been reported to be expressed poorly in asthma [23]. Additionally, RT-qPCR (Fig. 2B) identified the downregulation of miR-224-5p in asthma at a highest fold change among the 11 miRNAs. Thus, miR-224-5p was selected for following experiments.
Besides, the presence of a miR-224-5p-FHL1 binding site was predicted (Fig. 2C), which was further verified by dual-luciferase report gene assay (Fig. 2D). The luciferase activity of WT-FHL1 was inhibited by miR-224-5p mimic, but that of mut-FHL1 remained unaffected. Furthermore, miR-224-5p restoration
resulted in decreased FHL1 expression in isolated mouse ASMCs (Fig. 2E, F).

To sum up, FHL1 was negatively regulated by miR-224-5p in ASMCs from asthmatic mice.
Knockdown of FHL1 alleviates airway inflammation in mice with asthma-like airway inflammation

We then manipulated FHL1 expression in asthmatic mice, and validated that oe-FHL1 successfully upregulated FHL1 and sh-FHL1 reduced FHL1 expression (Fig. 3A). In terms of airway responsiveness assessment, FHL1 knockdown lowered airway resistance, and forced FHL1 expression enhanced airway resistance in response to Mch over 30 mg/mL (Fig. 3B). When the dosage of Mch reached 200 mg/mL, all asthmatic mice displayed higher airway resistance on the 1st day than on the 7th and 14th day. Besides, asthmatic mice presented with higher airway resistance and lower PC100 logarithms than normal mice. The increases in airway resistance and airway reactivity were enhanced in response to FHL1 overexpression yet repressed by FHL1 silencing (Fig. 3C–D), suggesting that silencing of FHL1 suppressed airway response activity.

Moreover, it was also revealed that the number of total cells and the percentage of eosinophils in BALF of asthmatic mice were attenuated by FHL1 knockdown, all of which were increased in asthmatic mice overexpressing FHL1 (Fig. 3E–F).

As shown by HE staining and Masson's trichrome staining in Fig. 3G–H, the asthmatic mice exhibited obviously augmented inflammatory cell infiltration (mainly eosinophils and lymphocytes) around the airway mucosa and blood vessel wall, thickened airway wall and ASM, increased folds of the mucosal epithelium, narrowed lumen partly blocked by mucus plugs, and increased staining area around bronchus and content of lung collagen. However, the asthmatic mice with sh-FHL1 exhibited orderly arranged epithelium of airway mucosa, slight damage of lung tissues, and reduced thickness of bronchial wall and content of collagen. The
lung tissue injury of asthmatic mice was aggravated after overexpression of FHL1. Overall, FHL1 downregulation could relieve airway inflammation and ameliorate lung tissue damage in the asthmatic mice.

**Silencing of FHL1 inhibits proliferation and induces apoptosis of ASMCs**

ASMCs were isolated from asthmatic mice to investigate the effect of FHL1 on ASMCs. The isolated cells were spindle-shaped, presented abundant cytoplasm and centered nucleus, and high-density cells presented partially overlapping peak (Fig. 4A), suggesting that the isolated cells were ASMCs. Higher expression of FHL1 mRNA was observed in ASMCs derived from asthmatic mice (Fig. 4B).

MTT assay, flow cytometry, and Western blot analysis subsequently unveiled enhanced viability of ASMCs, fewer cells arrested at the G1/G0 phase, more cells arrested at S phase, decreased cell apoptosis, and reduced proteins levels of cleaved PARP and cleaved caspase-3 in the ASMCs from asthmatic mice, which were reversed by silencing of FHL1 but intensified in response to forced FHL1 expression (Fig. 4C–F).

Taken together, loss of FHL1 function impaired ASMC viability and promoted their apoptosis.

**MiR-224-5p alleviates airway inflammation and lung tissue damage in asthmatic mice by targeting FHL1**

miR-224-5p was overexpressed in asthmatic mice to characterize whether the function of miR-224-5p in asthma was achieved by targeting FHL1. We observed a reduction in FHL1 expression and an increase in miR-224-5p expression in lung tissues of asthmatic mice treated with miR-224-5p-agomir, while oe-FHL1 treatment restored FHL1 expression (Fig. 5A).

In response to Mch at a dosage over 30 mg/mL or a dosage of 200 mg/mL (Fig. 5B–D), ectopic expression of miR-224-5p weakened airway resistance and airway responsiveness, while restoration of FHL1 reversed this effect.

The percentage of eosinophils was reduced when miR-224-5p was overexpressed, which was reversed following further upregulation of FHL1 (Fig. 5E). Moreover, miR-224-5p overexpression reduced the number of total cells and the percentage of eosinophils in the BALF and the secretion of inflammatory factors (IL-4, IL-5, IL-13, and IFN-γ) in BALF supernatant of asthmatic mice, which were negated by the further FHL1 overexpression (Fig. 5E–F).

According to the results of HE staining and Masson’s trichrome staining (Fig. 5G–H), asthmatic mice treated with NC-agomir or the combination of
miR-224-5p-agomir and oe-FHL1 displayed a large amount of inflammatory cell infiltration (mainly eosinophils and lymphocytes) around the airway mucosa and blood vessel wall. Meanwhile, we also observed thickened airway wall and smooth muscle, increased folds of the mucosal epithelium, narrowed lumen, some lumen blocked by mucus plugs, and increased staining area around bronchus and content of lung collagen. Besides, the asthmatic mice treated with miR-224-5p-agomir exhibited orderly arranged epithelium of airway mucosa, slight damage of lung tissues, and reduced thickness of bronchial wall and content of collagen.

Altogether, our data indicated that overexpression of miR-224-5p ameliorated airway inflammation and lung tissue damage in the asthmatic mice by inhibiting FHL1.

Silencing of FHL1 represses the MAPK pathway in vivo
Evidence exists reporting that activation of the MAPK pathway is associated with asthma [29, 30] and FHL1 can regulate the MAPK pathway [18]. The schematic diagram of the binding of MAPK pathway protein ERK to...
Fig. 6  Silencing of FHL1 blocks the MAPK pathway in vivo. Normal mice served as the control and asthmatic mice were treated with lentivirus harboring oe-FHL1/oe-NC or sh-FHL1/sh-NC. A Schematic diagram of the binding of MAPK pathway protein ERK to the LIM domain of FHL1, which is composed of four LIM domains (lim1-4) and an additional N-terminal half LIM domain (z). B mRNA levels of FHL1, ERK, p38MAPK and JNK in lung tissues of asthmatic mice determined by RT-qPCR. C Protein levels of FHL1, ratio of p-ERK/ERK, ratio of p-p38MAPK/p38MAPK, and ratio of p-JNK/JNK in lung tissues of asthmatic mice measured by Western blot analysis. D Immunohistochemical analysis of protein expression of p-ERK, p-p38MAPK, and p-JNK in lung tissues of asthmatic mice. n = 10 mice for each treatment. * p < 0.05 compared with normal mice. # p < 0.05 compared with asthmatic mice treated with lentivirus harboring sh-NC. $ p < 0.05 compared with asthmatic mice treated with lentivirus harboring oe-NC.
MiR-224-5p inhibits proliferation and enhances apoptosis of ASMCs by repressing FHL1. ASMCs were transduced with miR-224-5p mimic/NC-mimic or in combination with oe-FHL1/oe-NC. 

A) Expression of miR-224-5p and FHL1 in ASMCs determined by RT-qPCR.
B) ASMC proliferation examined by MTT assay.
C) Protein levels of cleaved PARP and cleaved caspase-3 in ASMCs measured by Western blot analysis.
D) Flow cytometric data showing cell cycle distribution.
E) Flow cytometric data showing cell apoptosis. * p < 0.05 compared with ASMCs transduced with NC-mimic. # p < 0.05 compared with ASMCs transduced with miR-224-5p-mimic + oe-NC. Cell experiments were performed in triplicate.
the LIM domain of FHL1 is shown in Fig. 6A. Therefore, we speculated that aberrant expression of FHL1 may mediate the MAPK pathway in asthma.

We confirmed that the mRNA levels of FHL1, ERK, p38MAPK and JNK as well as the protein levels of FHL1, ratio of p-ERK/ERK, ratio of p-p38MAPK/p38MAPK, and ratio of p-JNK/JNK in lung tissues of asthmatic mice determined by Western blot analysis. Hence, downregulation of FHL1 could block the activation of the MAPK pathway in asthma.

MiR-224-5p impairs ASM C proliferation and induces their apoptosis by suppressing FHL1

The expression of miR-224-5p and FHL1 was manipulated in ASMCs to explore their impacts on the biological functions of ASMCs. RT-qPCR suggested that miR-224-5p expression was upregulated while FHL1 expression was downregulated in miR-224-5p mimic-transfected ASMCs. By contrast, co-overexpression of miR-224-5p and FHL1 resulted in enhanced FHL1 expression relative to miR-224-5p upregulation alone (Fig. 7A).

MTT assay, flow cytometry, and Western blot analysis subsequently exhibited inhibited viability of ASMCs, more cells arrested at the G1/G0 phase, fewer cells arrested at S phase, promoted cell apoptosis, and elevated proteins levels of cleaved PARP and cleaved caspase-3 in the ASMCs from asthmatic mice in response to restored miR-224-5p, which were abolished after simultaneous overexpression of FHL1 (Fig. 7B–E).

Altogether, miR-224-5p could inhibit ASM C proliferation and facilitate their apoptosis by repressing FHL1 expression in vitro.

MiR-224-5p disrupts the activation of MAPK pathway by downregulating FHL1 in vivo

Finally, we determined the expression of the MAPK pathway-related molecules in the lung tissues of asthmatic mice. It was confirmed that mRNA levels of FHL1, ERK, p38MAPK, and JNK as well as the protein levels of FHL1, ratio of p-ERK/ERK, ratio of p-p38MAPK/p38MAPK, and ratio of p-JNK/JNK in lung tissues of asthmatic mice detected by immunohistochemical analysis. Hence, miR-224-5p could block the activation of the MAPK pathway through suppression of FHL1 in vivo.

Discussion

miRNAs have been identified as promising biomarkers in airway inflammation and the function of ASMCs in asthma [31, 32]. Herein, our study is conducted to explore the effects of miR-224-5p on airway inflammation in asthmatic mice and proliferation of ASMCs with the involvement of the FHL1-mediated MAPK pathway. Collectively, the results demonstrated an inhibitory property of miR-224-5p on airway inflammation and ASMC proliferation via disruption of the FHL1-mediated MAPK pathway.
Our study found that FHL1 was highly expressed in the lung tissues of asthmatic mice, and downregulation of FHL1 alleviated airway inflammation, inhibited ASMC proliferation, and promoted cell apoptosis in asthmatic mice. This finding corroborates that of a previous study, which has highlighted that FHL1 restricts the host adaptive immune response, and then triggers influenza A virus-induced lung inflammation [33]. FHL2, another FHL protein family member, serves as a new target for treating asthma, and silencing of FHL2 suppresses airway inflammation in OVA-induced asthmatic mice [34]. Another study has also demonstrated that FHL1 is a prominently upregulated protein in lung tissues from patients with idiopathic pulmonary arterial hypertension and its overexpression enhances migration and proliferation of pulmonary artery SMCs [35]. FHL1 knockdown arrested pulmonary artery SMCs at the G1 phase and dampened cell proliferation in hypoxia-induced pulmonary hypertension [12]. These evidences support the roles of FHL1 in the inhibition of airway inflammation and ASMC proliferation in asthmatic mice.

Of note, the mechanistic data revealed that FHL1 was targeted by miR-224-5p in asthma, and miR-224-5p was downregulated in lung tissues of asthmatic mouse. The functional experiments of our work highlighted that miR-224-5p alleviated airway inflammation, repressed proliferation and stimulated apoptosis of ASMCs in asthmatic mice. In line with our results, downregulation of miR-224 has also been previously observed in asthmatic patients [23]. The anti-asthmatic effect of miR-224-5p in OVA-induced experimental asthma has been documented to be achieved by restricting pro-inflammatory TLR2 expression [24]. The infiltration of inflammatory cells in OVA-induced experimental allergic rhinitis was appreciably diminished by miR-224 agomir, and this effect was associated with targeted inhibition of CDK9 [36]. The forced expression of miR-224-5p exerted protective effect against airway inflammation in asthmatic mice by targeting FHL1, and overexpressed FHL1 could offset its effect.

Furthermore, miR-224-5p has been documented to inactivate the MAPK/ERK pathway in rats with hypothyroidism [37]. MAPK pathway is correlated with some inflammatory responses of patients with asthma, such as the release of inflammatory proteins TGF-β1 and IL-13 [38]. Suppression of the MAPK pathway activation could curb ASMC proliferation, migration and subsequent airway remodeling in asthma [39]. Consistently, our data validated the suppression of miR-224-5p on the MAPK pathway activation, and further offered evidence reporting the implication of FHL1. Restored miR-224-5p blocked the MAPK pathway to ameliorate airway inflammation in asthmatic mice, while ectopic expressed FHL1 negated its effect. FHL1 is a biomechanical stress sensor that mediates the MAPK-activated pathway [18, 40], thus the miR-224-5p-impaired FHL1 expression could restrict the MAPK signaling. Therefore, we reasoned that miR-224-5p could ameliorate airway inflammation, repress proliferation of ASMCs by blocking activation of FHL1-MAPK pathway.

Conclusions

Overall, the present study demonstrated that miR-224-5p may act as an anti-asthma miRNA by suppressing airway inflammation in the OVA-induced asthmatic mice. Our study revealed that miR-224-5p could suppress ASMC-secreted inflammatory factors, including IL-4, IL-5, IL-13 and IFN-γ. Additionally, miR-224-5p repressed proliferation and promoted apoptosis of ASMCs by inhibiting FHL1-mediated MAPK pathway activation. Therefore, it is promising to develop therapeutic strategies targeting miR-224-5p for clinical use in the treatment of asthma. Moreover, the inner mechanisms of miR-224-5p and FHL1 in clinical tissue samples of asthma and the effect of miR-224-5p on mild or chronic asthma mouse models should be further explored and confirmed in the future.

Abbreviations

miRNAs: MicroRNAs; TLR2: Toll-like receptor 2; FC: Fold change; sh: Short hairpin RNA; miR-224-5p: MicroRNA-224-5p; FHL1: Four-and-a-half LIM protein 1; GEO: Gene expression omnibus; NCBI: National center for biotechnology information; JNK: C-Jun N-terminal kinase; MAPK: Mitogen-activated protein kinase; ASMCs: Airway smooth muscle cells; VEGF: Vascular endothelial growth factor; OVA: Ovalbumin; PBS: phosphate-buffered saline; BALF: Bronchoalveolar lavage fluid; H&E: Hematoxylin–eosin; oe: Overexpression; NC: Negative control; Mch: Methacholine; Bl: Inspiratory resistance; H$_2$O$_2$: Hydrogen peroxide; p: Phosphorylated; IgG: Immunoglobulin G; IFN-γ: Interferon-γ; IL: Interleukin; DAB, 3: 3'-Diaminobenzidine; ELISA: Enzyme linked immunosorbent assay; NC: Negative control; OD: Optical density; DMEM: Dulbecco’s modified Eagle’s medium; FBS: Fetal bovine serum; EDTA: Ethylene diamine tetraacetic acid; SP: Streptavidin–biotin-peroxidase; EDTA: Ethylene diamine tetraacetic acid; mut: Mutant; 3'-UTR: 3'-Untranslated region; RT-qPCR: Reverse transcription-quantitative polymerase chain reaction; CNDN: Complementary DNA; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; ERK: Extracellular signal-regulated kinase; BCA: Bicinchoninic acid; RIPI: Radioimmunoprecipitation assay; HRP: Horseradish peroxidase; ECL: Enhanced chemiluminescence; PVD: Polyvinylidene fluoride; BSA: Bovine serum albumin; MT: 4-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; FITC: Fluorescein isothiocyanate; PI: Propidium iodide; HEPES: 4-4-2-Hydroxyethyl)-1-piperazineethanesulfonic acid; DMSSO: Dimethyl sulfoxide; ANOVA: Analysis of variance; WT: Wild type.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13223-022-00724-9.
Acknowledgements
Net applicable.

Author contributions
ZZ conceived and designed research. YZ performed experiments and interpreted results of experiments. JX read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Institutional Animal Care and Use Committee of the Wujin Hospital Affiliated with Jiangsu University, and carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. Extensive efforts were made to ensure minimal suffering of the included animals.

Consent for publication
Not applicable.

Competing interests
The authors have declared that they have no competing interests.

Author details
1Wujin Hospital Affiliated with Jiangsu University, Changzhou 213002, People’s Republic of China. 2Wujin Clinical College of Xuzhou Medical University, Changzhou 213002, People’s Republic of China.

Received: 17 January 2022 Accepted: 4 September 2022
Published online: 02 October 2022

References
1. Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184(6):1469–85.
2. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783–800.
3. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65.
4. Camoretti-Mercado B, Lockey RF. Airway smooth muscle pathophysiology in asthma. J Allergy Clin Immunol. 2021;147(6):1983–95.
5. Jo MH, Kim BC, Sung K, Panettieri RA Jr, An SS, Liu J, Ha T. Molecular nanomechanical mapping of histamine-induced smooth muscle cell contraction and shortening. ACS Nano. 2021. https://doi.org/10.1021/acsnano.1c01782.
6. Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, Shih CM. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radiac Biol Med. 2012;52(2):577–91.
7. Young RE, Jones MK, Hines EA, Li R, Luo Y, Shw Y, Verheyden JM, Sun X. Smooth muscle differentiation is essential for airway size, tracheal cartilage segmentation, but dispensable for epithelial branching. Dev Cell. 2020;53(1):73-85.e5.
8. Salter B, Pray C, Radford K, Martin JG, Nair P. Regulation of human airway smooth muscle cell migration and relevance to asthma. Respir Res. 2017;18(1):156.
9. Andre-Gregoire G, Dillasser F, Chesne J, Braza F, Magnan A, Loirand G, Sauzeau V. Targeting of Rac1 prevents bronchoconstriction and airway hyperresponsiveness. J Allergy Clin Immunol. 2018;142(3):824-33.e3.
10. Wei X, Zhang H. Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression. Cancer Biol Med. 2020;17(2):270–81.
11. Li Y, Pu G, Chen C, Yang L. Inhibition of FHL1 inhibits cigarette smoke extract-induced proliferation in pulmonary arterial smooth muscle cells. Mol Med Rep. 2015;12(3):3801–8.
12. Yue J, Guan J, Wang X, Zhang L, Yang Z, Ao Q, Deng Y, Zhu P, Wang G. MicroRNA-206 is involved in hypoxia-induced pulmonary hypertension through targeting of the HIF-1alpha/FN-1 pathway. Lab Invest. 2013;93(7):748–59.
13. Zhong S, Chen C, Liu N, Yang L, Hu Z, Duan P, Shuai D, Zhang Q, Wang Y. Overexpression of hsa-miR-644a-3p is associated with cigarette smoke-induced chronic obstructive pulmonary disease via targeting FHL1. Int J Chron Obstruct Pulmon Dis. 2019;14:2319–29.
14. Hu M, Ou-Yang HF, Han XP, Ti XY, Wu CG. KyoT2 downregulates airway remodeling in asthma. Int J Clin Exp Pathol. 2015;8(11):14171–9.
15. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat App Genet Mol Biol. 2004;3:1.
16. Wei DZ, Guo XY, Lin LN, Lin MX, Geng YQ, Ying BY, Huang MY. Effects of angelicin on ovalbumin (OVA)-induced airway inflammation in a mouse model of asthma. Inflammation. 2016;39(6):1876–82.
17. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52(7):893–901.
18. Sheikh F, Raskin A, Chu PH, Lange S, Domenighetti AA, Zheng M, Liang X, Zhang T, Rajjama T, Gu Y, Dalton ND, Mahaka SK, Dom GW 2nd, Brown JH, Peterson KL, Omens JH, McCulloch AO, Chen J. An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J Clin Invest. 2008;118(12):3870–80.
19. Dong X, Xu M, Ren Z, Gu L, Mu Q, Zhong N. Regulation of CBL and cSRC expression by microRNA-223 promotes the pathogenesis of dust mite-induced pediatric asthma. Int J Mol Med. 2016;38(2):446–56.
20. Munoz L, Ramsay EE, Manetsch M, Ge Q, Peifer C, Lauffer S, Ammit AJS. Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. Eur J Pharmacol. 2010;635(1–3):212–8.
21. Koch A, Raidl M, Lux M, Muller K, Bunung H, Humme S, Erdmann E. IL-12-induced T-bet expression and IFN-gamma release in lymphocytes from asthmatics–role of MAPKinases ERK-1/2, p38(MAPK) and effect of dexamethasone. Respir Med. 2007;101(6):1321–30.
22. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 2011;108(9):3713–8.
23. Susajalehto H, Lindstrom I, Majun ML, Mitts C, Karjalainen J, Wolff H, Alenius H. Altered microRNA expression of nasal mucosa in long-term asthma and allergic rhinitis. Int Arch Allergy Immunol. 2014;163(3):168–78.
24. Li P, Wang J, Guo F, Zheng B, Zhang X. A novel inhibitory role of microRNA-224 in particulate matter 2.5-μm induced asthmatic mice by inhibiting TLR2. J Cell Mol Med. 2020;24(5):3040–52.
25. Dong L, Wang Y, Zheng T, Pu Y, Ma Y, Qi X, Zhang W, Yue F, Shan Z, Liu J, Wang X, Mao C. Hypoxic HUCMSC-derived extracellular vesicles attenuate allergic airway inflammation and airway remodeling in chronic asthma mice. Stem Cell Res Ther. 2021;12(1):4.
26. Song MK, Kim DI, Lee K. Causal relationship between humidifier disinfectant exposure and Th17-mediated airway inflammation and hyperresponsiveness. Toxicology. 2021;454:152739.
27. Thanawala VJ, Forkuo GS, Al-Sawalha N, Azeggagh Z, Nguyen LP, Eriksen JL, Tuvim MJ, Lowder TW, Dickey BF, Knoll BJ, Walker JK, Bond
beta2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model. Am J Respir Cell Mol Biol. 2013;48(2):220–9.

28. Sun X, Zheng X, Zhang X, Zhang Y, Luo G. Exosomal microRNA-23b-3p from bone marrow mesenchymal stem cells maintains T helper/Treg balance by downregulating the PI3K/Akt/NF-kappaB signaling pathway in intracranial aneurysm. Brain Res Bull. 2020;165:305–15.

29. Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest. 2011;139(6):1470–9.

30. Li Y, Li GP. Oxidative stress in asthma: a distinct clinical and pathologic feature? J Biol Regul Homeost Agents. 2016;30(4):1053–7.

31. Tay HL, Plank M, Collison A, Mattes J, Kumar RK, Foster PS. MicroRNA: potential biomarkers and therapeutic targets for allergic asthma? Ann Med. 2014;46(8):633–9.

32. Deshpande DA, Dileepan M, Walseth TF, Subramanian S, Kannan MS. MicroRNA regulation of airway inflammation and airway smooth muscle function: relevance to asthma. Drug Dev Res. 2015;76(6):286–95.

33. Masemann D, Leite Dantas R, Sitnik S, Schied T, Nordhoff C, Ludwig S, Widler V. The Four-and-a-Half LIM domain protein 2 supports influenza virus-induced lung inflammation by restricting the host adaptive immune response. Am J Pathol. 2018;188(5):1236–45.

34. Kurakula K, Vos M, Logiantara A, Roelofs JJ, Nieuwenhuis MA, Koppelman GH, Postma DS, Brandisma CA, Sin DD, Bosse Y, Nickle DC, van Rijt LS, de Vries CJ. Deficiency of FHL2 attenuates airway inflammation in mice and genetic variation associates with human bronchial hyper-responsiveness. Allergy. 2015;70(12):1531–44.

35. Kwapiszewska G, Wygrecka M, Marsh LM, Schmitt S, Trosser R, Wilhelm J, Helmus K, Eul B, Zakrzewicz A, Ghofrani HA, Schermuly RT, Bohle RM, Grimminger F, Seeger W, Eckelberg D, Fink L, Weissmann N. Phl-1, a new key protein in pulmonary hypertension. Circulation. 2008;118(11):1183–94.

36. Wang S, Wang L, Hu H, Dong P. MiR-224 ameliorates inflammation and symptoms in mouse model of allergic rhinitis by targeting CDK9. Allergol Immunopathol (Madr). 2021;49(6):80–8.

37. Wang C, Zhu J, Zhang Z, Chen H, Ji M, Chen C, Hu Y, Yu Y, Xia R, Shen J, Gong X, Wang SL. Rho-miR-224–5p contributes to 2,2',4,4'-tetrabromodiphenyl ether-induced low triiodothyronine in rats by targeting deiodinases. Chemosphere. 2020;246:125774.

38. Zhou X, Hu H, Balzar S, Trudeau JB, Wenzel SE. MAPK regulation of IL-4/IL-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-beta1 and IL-13 in human airway fibroblasts. J Immunol. 2012;188(12):6046–54.

39. Zhang QJ, Chen HZ, Wang L, Liu DP, Hill JA, Liu ZP. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Invest. 2011;121(6):2447–56.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.